☆ 4.6 Editorial Material

Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer

FRONTIERS IN ONCOLOGY (2021)

Get Full Text
Add to Collection

Journal

FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.632657

Keywords

drug repositioning; resistant cancer; P-gp overexpresssion; MDR; anticancer drug; molecular targeting; lower toxicity; cancer stem cell

Categories

Oncology

Funding

  1. National Research Foundation of Korea (NRF) - Ministry of Education [NRF-2019R1A2C2002923]
  2. Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.